Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-03-28
2006-03-28
Hui, San-Ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
07018992
ABSTRACT:
Twice weekly administration of an analog to a Vagifem tablet which only contains 10 μg of active material has a sufficient effect.
REFERENCES:
patent: 6060077 (2000-05-01), Meignant
patent: WO 97/12600 (1997-04-01), None
Smith et al., Maturitas, 1993;16(2):145-154.
Vagifem monograph, Novo Nordisk, Jun. 2000.
McCane, “Pathophysilogy: the biologic basis for disease in adults and children”, published by Mosby, 1990, p. 989.
Mettler et al., Maturitas, vol. 14, pp. 23-31 (1991).
Kvorning et al., Saidioc and Eriksen, Editors, The Urogenital Oestrogen Deficiency Syndrome, Proceedings of the International Workshop, Copenhagen, pp. 51-60 (1986).
Nilssom et al., Mamriras, vol. 15, pp. 121-127 (1992).
Dugal et al., Acta Obstet. Gynecol. Scan., vol. 79, pp. 293-297 (2000).
Koch Karen
Kvorning Ingelise
Bork Richard
Green Reza
Hui San-Ming
Novo Nordisk A S
Smith Len S.
LandOfFree
Hormone composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hormone composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hormone composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3536289